Actinogen Medical : ACW CEO Presents at San Francisco Healthcare Conference

For personal use only

ASX ANNOUNCEMENT

Actinogen CEO presents at JP Morgan Annual HealthCare Conference Week

Sydney, 10 January 2022. Actinogen Medical ASX: ACW ("ACW" or "the Company") CEO Dr Steven Gourlay will present at the Biopartnering @JPM associated with the 40th annual JP Morgan HealthCare Conference in San Francisco from 10 to 13 January 2022. While in San Francisco, Dr Gourlay will also present at the H.C. Wainwright BioConnect Virtual Conference that runs concurrently with the JP Morgan conference.

Dr Gourlay will conduct multiple business development and other stakeholder meetings during the conference week as well. The information used for all presentations and meetings is attached to this announcement.

The focus of Dr Gourlay's presentations and meetings is to update the industry on recent developments in the Company's clinical development pipeline, including:

• Progress in the Alzheimer's Disease (AD) XanaMIA Part A trial in older volunteers, with top line cognition data expected in Q2 CY2022
• Retrospective analysis of the effects of Xanamem® on "disease modifying" biomarkers using stored samples from the prior Phase 2 study in mild Alzheimer's Disease, with results expected in H2 CY2022
• Expansion of the Phase 2 XanaFX clinical trial for patients with Fragile X Syndrome (FXS) to include sites in North America and a new 5mg dose group, with planned enrolment increased from 50 to 75. The trial is commencing following receipt of US FDA IND approval in November 2021, and results are expected in 2023
• Selection of Major Depressive Disorder (MDD) as the third indication for Xanamem trials, based on a strong scientific rationale, with a randomised phase 2 clinical trial scheduled to commence in 2022. Results are expected in 2023.

Dr Steven Gourlay, Actinogen CEO and MD, commented:

"We are delighted to update potential pharmaceutical industry partners on our expanded clinical development pipeline and its multiple near and medium-term milestones.

"Despite the worldwide COVID-19 situation it is pleasing to see strong ongoing interest and activity at the JP Morgan conference. This is especially true of the Alzheimer's Disease field that was boosted by the 2021 approval of Aduhelm based largely on the surrogate of amyloid protein as a biomarker.

"Actinogen is actively exploring the effects of its lead molecule, Xanamem, on a range of biomarkers that could indicate modification of underlying disease.

"Actinogen's clinical development pipeline is designed to fulfil our vision of making a material difference to the quality of life for people and their families living with serious neurological conditions like Alzheimer's Disease, Fragile X Syndrome, and Depression."

• Xanamem is a registered trademark of Actinogen Medical Limited

Actinogen Medical Limited ACN 086 778 476

1

Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 [phone] |actinogen.com.au

ENDS

For personal use only

	Investors	Media
Dr. Steven Gourlay	Michael Roberts	Randal Killip
CEO & Managing Director	Investor Relations	Profile for Media
P: [phone]	P: [phone]	M: [phone]
[e-mail]	[e-mail]	[e-mail]

Announcement authorised by the Board of Directors of Actinogen Medical

About Actinogen Medical

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.

Cognitive function means how a person understands, remembers and thinks clearly. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influence our personality.

We are currently developing our lead compound, Xanamem®, as a promising new therapy for Alzheimer's Disease, Fragile X Syndrome, Depression and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem®

Xanamem's novel mechanism of action works by blocking the production of intracellular cortisol through the inhibition of the 11β-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing the drug capsule.

Chronically elevated cortisol is associated with cognitive decline in Alzheimer's Disease, potentially linked to cognitive impairment and anxiety in Fragile X Syndrome, and cognitive impairment and underlying disease in Depression and other diseases.

The Company has studied 11β-HSD1 inhibition by Xanamem in more than 250 volunteers and patients, so far finding a statistically significant improvement in cognition over placebo in healthy, older volunteers. A series of Phase 2 studies in multiple diseases is being conducted to further confirm and characterise Xanamem's therapeutic potential.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies, and regulatory and clinical development risks and uncertainties) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP.

Actinogen Medical Limited ACN 086 778 476

2

Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 [phone] |actinogen.com.au

ersonal use only

JP Morgan Update Presentation

Dr. Steven Gourlay MBBS PhD MBA: CEO & MD, CMO

January 10, 2022

NON-CONFIDENTIAL

ersonal use only

H.C. Wainwright BioConnect Conference

January 10-13, 2022

Update presented by Steven Gourlay MBBS PhD, CEO

NON-CONFIDENTIAL

ersonal use only

Disclaimer

This presentation has been prepared by Actinogen Medical Limited. ("Actinogen" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

This presentation is not for general distribution or third party reliance or use.

This presentation contains certain budget information, forecasts and forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management in respect of which there is NO guarantee of future performance. Such budget information, forecasts and forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to the performance of Actinogen in its clinical trials including whether it's technology proves to be a safe and effective treatment, market penetration, competition from any other similar products, intellectual property risks (including securing rights in technology and patents) and global economic conditions. Furthermore, Actinogen's research, product development, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. There is no guarantee that Actinogen will obtain the required approvals, licences and registrations from the relevant authorities in jurisdictions in which it operates. Actinogen or others could identify product and efficacy issues relating to the safety of our technology. Accordingly, all forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. There is no guarantee that Actinogen will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realised. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward- looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Neither Actinogen nor any other entity or person in or associated with Actinogen guarantee any return (whether capital or income) or generally the performance of Actinogen or the price at which its securities may trade. Any investment in Actinogen is subject to investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends.

To the maximum extent permitted at law, Actinogen and all of its representatives, directors, officers, partners, employees or professional advisers (Parties) exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), the Parties do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this presentation or any accompanying, previous or subsequent material or presentation.

3